SES Logo

SYSTEMIC ENZYME SUPPORT.org

 

Psoriasis

Psoriasis is another one of those conditions that require dietary changes as well. But even then, it is difficult to get rid of because – again - because the body is stuck in a chronic cycle of inflammation.
Psoriasis is another one of those conditions that have high amount of the pro-inflammatory cytokine TNF-alpha (tumor necrosis factor alpha). It is known that TNF alpha is elevated in both the skin patients with psoriasis. We also know that Wobenzym decreases TNF-alpha levels.
So, it should come as no surprise, when we learn that when Wobenzym is used, there is a marked improvement of clinical symptoms and as well as laboratory values in patients with psoriasis.
                                                         From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND
                                                         Read the special section:
SKIN CONDITIONS & WOBENZYM®

What the literature says about Systemic Enzyme Support and:

Psoriasis

Wobenzym in the treatment of patients with psoriasis.v 

Milus I.E. Wobenzym in the treatment of patients with psoriasis. Zurnal dermatologii i venerologii 1998, 2 (6), 35-36. [Ukrainian]vDonetsk Medical University.  

58 patients (37 women, 21 men), aged 2-58 years, suffering from various forms of psoriasis were observed. All patients underwent complex, clinico-laboratory examination.v
Patients were divided into 4 groups:

    ·        
Control - 15 patients, received a conventional therapy (vitamins, biostimulators, immunocorrectors, fyziotherapy, and softening ointments).
    ·        
Complex treatment including Wobenzym (3 tablets 3 times a day for 30 days) - 16 patients
    ·        
Complex therapy including external application of Wobe Mugos ointment - 6 patients
    ·        
Complex therapy including both Wobenzym and Wobe Mugos - 21 patients
Treatment was well tolerated by all patients. In patients in groups 2 and 4, receiving Wobenzym, a significant decrease of exsudative component of exacerbation was observed after 3-5 days of treatment. Resting stage of the disease occurred in group 1 after 7-9 days of treatment, in patients in groups 2 and 4 after 3-5 days. Complete regression was achieved in group 1 after 28-32 days of treatment, in group 2 after 24-26 days, in group 3 after 26-28 days, and in group 4 after 18-20 days. Dynamics as well as the exacerbation regression were accompanied by a marked tendency to the normalization of biochemical, immunological parameters (most significant in groups 2 and 4).
Results obtained within one year proved a high efficacy of polyenzyme preparations in the complex treatment of psoriasis. Disease recurrence within 6-12 months was diagnosed in 6 out of 15 patients in group 1, while only in 7 out of 37 patients in enzyme treated groups 2 and 4.
Poster Reference Number 56.  

Systemic enzyme therapy in dermatology and venerology: perspectives of its use.  

Protsenko T.V. Systemic enzyme therapy in dermatology and venerology: perspectives of its use. Zurnal dermatologii i venerologii 1998, 2(6), c.12-13. State Medical Uiniversity, Donetsk, Ukraine [Abstract in Russian.]  

255 patients (36 – chlamydiosis, 46 –lues, 43 – psoriasis, 48 – sclerodermia, 35 – various forms of alopecia, 25 – granuloma anulare, 22 – lipoid necrobiosis) were observed for more than 2 years.
Especially important was a complex treatment of chlamydiosis and lues patients combined with Wobenzym. Patients received Wobenzym 5-3 dragees 3 times a day in combination with conventional antibacterial therapy. SET enhanced significantly therapy efficacy, in some cases even enabled to omit conventional drugs.
Patients suffering from dermatological diseases received Wobenzym (9-15 dragees daily for at least 4 weeks) and Wobe-Mugos ointment locally. A marked improvement of clinical symptoms and laboratory parameters was seen in 61.5% patients, improvement in 19.8%.
No side-effects were reported in all 255 patients.